DR. REDDY'S

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. : 3, Banjara Hills
Hyderabad - 500 034, A.P., India.
Tel : + 91 40 4900 2900
Fax : +91 40 4900 2999

www.drreddys.com

April 4, 2013

Corporate Relationship Department
BSE Limited
Dala Street, Fort
Mumbai – 400 001
Fax No.: 022-22723121 / 22723719 /
22722037/ 22722039

National Stock Exchange of India Ltd.
"Exchange Plaza"
Bandra-Kurla Comples, Bandra (East),
Mumbai – 400 051
Fax No.: 022-26598120 / 26598237 /
26598238

***Scrip Code :* 500124**

Scrip Code :* DRREDDY-*EQ

Dear Sirs,

Sub: Press Release

Please find enclosed a **Press Release** on **"Dr. Reddy's Announces the Launch of Zoledronic Acid Injection".**

Kindly arrange to disseminate and display the same on your Notice Board for the purpose of information.

With regards,

Sandeep Poddar
Company Secretary

Encl: as above

CC: New York Stock Exchange Inc. (Stock Code: RDY)

Press Release

DR. REDDY'S

Dr. Reddy's Announces the Launch of Zoledronic Acid Injection

Hyderabad, India, April 04, 2013

Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (5 mg/100 mL), a therapeutic equivalent generic version of Reclast® (zoledronic acid) Injection 5 mg/100 mL in the US market on April 03, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy's ANDA for Zoledronic Acid Injection (5 mg/100 mL).

The Reclast® brand had total U.S. sales of approximately $355 million for the most recent twelve months ending February 2013 according to IMS Health*.

Dr. Reddy's Zoledronic Acid Injection (5 mg/100 mL) is available in a single use vial for Intravenous Infusion.

Disclaimer

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy's

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - *Pharmaceutical Services and Active Ingredients*, *Global Generics* and *Proprietary Products* – Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: www.drreddys.com

Reclast® is a registered trademark of Novartis AG.
*IMS National Sales Perspectives: Retail and Non-Retail MAT February 2013

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at kedaru@drreddys.com /+91-40-66834297
Saunak Savla at saunaks@drreddys.com/+91-40-49002135
Milan Kalawadia (USA) at mkalawadia@drreddys.com/ +1 908-203-4931

Media:
S Rajan at rajans@drreddys.com/ +91-40- 49002445

Dr. REDDY'S LABORATORIES LTD. HYDERABAD-INDIA